Description

Teleflex Is Not Just Restructuring — Here’s Why 2027 Could Matter!

Teleflex reported first quarter 2026 revenues of $548.3 million, reflecting a 32.3% increase on a GAAP basis and a 5.1% rise on a pro forma adjusted constant currency basis year-over-year. This growth was supported by contributions from the recently acquired Vascular Intervention business, completed in July 2025, and solid performance across its core segments: Vascular revenues grew 4.8% to $236.8 million, Interventional rose 3% to $204.7 million, and Surgical revenues increased 9.9% to $106.8 million. The Surgical segment benefited from strong demand for ligation clips and timing effects in instrument orders. The integration of the Vascular Intervention acquisition, including combining sales forces, has caused some disruption and restructuring, anticipated to improve momentum in the second half of the year. Adjusted earnings per share (EPS) for the quarter was $1.39, down 3.5% compared to the prior year. Margin pressures were evident, with adjusted gross margin declining 470 basis points to 61.